Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus
I'm LongbridgeAI, I can summarize articles.Prime Medicine released a corporate presentation highlighting its prime editing platform and liver disease pipeline. Key programs include PM577a for Wilson disease, with Phase 1/2 trials starting in H2 2026, and PM647 for AATD, expected to file IND/CTA in Q3 2026. The company also reported progress toward a BLA filing for the ex vivo CGD program PM359, targeting a commercial launch in 2027+. Additionally, Prime Medicine is pursuing cystic fibrosis proof-of-concept work and strategic partnerships.
- Prime Medicine highlighted a near-term focus on in vivo liver programs, led by Wilson disease candidate PM577a and AATD candidate PM647. * PM577a received CTA and IND clearance; a Phase 1⁄2 trial is slated to start in H2 2026, with initial clinical data targeted in 2027. * PM647 is expected to have an IND and/or CTA filing in Q3 2026; initial clinical data is targeted in 2027. * The company also flagged progress toward a BLA filing for ex vivo CGD program PM359, with a commercial launch planned for 2027+. * Pipeline expansion priorities include cystic fibrosis proof-of-concept work and additional strategic partnerships to accelerate development and strengthen funding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here